A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

Trial Profile

A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs Yifenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Pharmacokinetics
  • Sponsors Sunshine Lake Pharma
  • Most Recent Events

    • 16 Apr 2018 Planned End Date changed from 15 May 2018 to 15 Aug 2018.
    • 16 Apr 2018 Planned primary completion date changed from 15 Jan 2018 to 15 Jun 2018.
    • 16 Apr 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top